Aclarion Says USPTO Issues Notice Of Allowance For U.S. Patent Application Titled Multi-Voxel Prescription For Lumbar Disc Evaluation

Aclarion, Inc.

Aclarion, Inc.

ACON

0.00
  • Patent protects the precision of MRS data capture within the target disc — a critical step in the Nociscan workflow
  • Designed to reduce scan time, support faster technologist onboarding and deliver more reproducible results across imaging centers
  • Extends Aclarion's IP protection to over 65 issued and pending patents worldwide, complementing its broader portfolio covering spectroscopy acquisition, data processing, biomarkers and analytics
     

BROOMFIELD, Colo., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-stage healthcare technology company leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced that the United States Patent and Trademark Office ("USPTO") has issued a Notice of Allowance for U.S. Patent Application titled "Multi-Voxel Prescription for Lumbar Disc Evaluation."

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.